MENU

Sergei Grivennikov Appointed to AACR Tumor Microenvironment Steering Committee

November 11, 2019

Dr. Grivennikov’s two-year term on the committee begins at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2020, which is being held April 24-29 in San Diego, CA. The Tumor Microenvironment Working Group formed in 2006 to improve scientific contributions to this area of cancer research.Dr. Grivennikov’s two-year term on the committee begins at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2020, which is being held April 24-29 in San Diego, CA. The Tumor Microenvironment Working Group formed in 2006 to improve scientific contributions to this area of cancer research.

PHILADELPHIA (November 11, 2019) – The leadership of the Tumor Microenvironment Working Group of the American Association for Cancer Research has appointed Sergei Grivennikov, PhD, associate professor in the Cancer Prevention and Control Program at Fox Chase Cancer Center, to the Steering Committee of its Tumor Microenvironment Working Group.

The tumor microenvironment consists of various cells surrounding cancer cells that determine how tumors grow and gives clues as to how they may be attacked with therapies.

“I’m looking forward to working with others on the committee and advancing ideas about the importance of the tumor microenvironment,” Grivennikov said. His lab studies the molecular and cellular mechanisms underlying how immune and inflammatory pathways promote tumor growth and progression.

Grivennikov’s two-year term on the committee begins at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2020, which is being held April 24-29 in San Diego, CA. The Tumor Microenvironment Working Group formed in 2006 to improve scientific contributions to this area of cancer research.

As a Steering Committee member, Grivennikov will make suggestions to the AACR for speakers, workshops, meetings, and special conferences on the topic of the tumor microenvironment organized by AACR. He will also promote innovative research in the field of tumor microenvironment.  

       

The Hospital of Fox Chase Cancer Center and its affiliates (collectively “Fox Chase Cancer Center”), a member of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence five consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.
For more information, call 1-888-FOX CHASE or (1-888-369-2427).

Connect with Fox Chase